For hypertensive patients who need the combination of antihypertensive drugs, Lercanidipine Hydrochloride and Irbesartan Tablets are the recommended first-line regimen, and the combination of these two drugs can lower the blood pressure and control it within a reasonable range. 1. Lercanidipine hydrochloride is a new generation of dihydropyridine calcium channel blocker (CCB), which can diastole vascular smooth muscle, with significant antihypertensive effect, long duration of action and small negative muscle force. It is contraindicated in patients who are allergic to Lercanidipine, pregnant and lactating women, left ventricular outflow tract obstruction, untreated congestive heart failure, unstable angina pectoris, severe hepatic impairment, and within one month of myocardial infarction. 2. Irbesartan is a selective angiotensin-II receptor antagonist (ARB), which has the effect of vasodilating and lowering blood pressure. Irbesartan is contraindicated in patients who are allergic to Irbesartan, in the 4th to 9th month of pregnancy, and in nursing mothers. Lercanidipine reduces the risk of stroke in patients with hypertension; Irbesartan reduces the incidence of cardiovascular complications and the risk of cardiovascular events in patients with a history of cardiovascular disease, reduces proteinuria and microproteinuria in patients with diabetes or nephropathy, and also prevents atrial fibrillation. When using the combination program to follow the doctor’s instructions, do not adjust the dose or stop the drug, in order to avoid affecting the efficacy of the treatment and the emergence of adverse reactions. If adverse reactions occur, you should promptly go to the hospital for treatment.